Asthma
Conditions
Brief summary
The impact of a pharmacist's intervention on asthma control has now been well demonstrated, but its effect on inflammatory markers of FENO (Fractional exhaled nitric oxide) in asthmatic patients has been little studied in the literature. The aim of this study is to investigate the impact of a pharmacist's intervention on FENO in patients seen in clinical practice by a pneumologist in a secondary university center.
Interventions
Pharmacist's intervention with asthmatic patients: * Detailed questionnaire on asthma and treatments (atopy, comorbidities, smoking status, asthma control, adverse effects of treatments, etc.) * Explanation of asthma and inflammation * Explanation of triggers and how to avoid it * Explanation of asthma treatments * Explanation of the inhalation technique with a physical demonstration * Emphasis on treatment adherence * Assessment of comorbidities and their treatment * Emphasis on influenza vaccination
OTHERQuestionnaires for control group
\- Detailed questionnaire on asthma and treatments (atopy, comorbidities, smoking status, asthma control, adverse effects of treatments, etc.)
Sponsors
University of Liege
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Adult asthmatics (definition of asthma: FEV1 \[forced expiratory volume in 1 second\] reversibility of at least 12% and 200 mL after 400 mcg of salbutamol and/or PC20M \[provocative concentration of methacholine causing a 20% fall in FEV1\]\<16 mg/mL) * unchanged or increased dose of inhaled corticosteroids prescribed by the pneumologist at the visit * FENO (fractional exhaled nitric oxide) \> or = 25 ppb
Exclusion criteria
* Treatment with oral corticosteroids to treat an asthma exacerbation within 4 weeks before the visit with the pneumologist
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline FENO (fractional exhaled nitric oxide) at 3 months | 3 months | Fractional exhaled nitric oxide |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline FVC (forced vital capacity) at 3 months | 3 months | — |
| Change from Baseline FEV1/FVC at 3 months | 3 months | — |
| Change from Baseline ACQ (Asthma Control Questionnaire) at 3 months | 3 months | — |
| Change from Baseline ACT (Asthma Control Test) at 3 months | 3 months | — |
| Change from Baseline miniAQLQ (Asthma Quality of Life Questionnaire) at 3 months | 3 months | — |
| Change from Baseline MARS (Medication Adherence Report Scale) at 3 months | 3 months | Measure of treatment adherence |
| Change from Baseline FEV1 (forced expiratory volume in 1 second) at 3 months | 3 months | — |
| Change from Baseline score of the inhalation technique at 3 months | 3 months | — |
| Change from Baseline number of severe exacerbations (during the 3 previous months) at 3 months | 3 months | Severe exacerbations are asthma exacerbations requiring oral corticosteroids |
| Change from Baseline smoking status at 3 months | 3 months | Smoking status is recorded as non-smoker, ex-smoker, current smoker |
| Satisfaction of patients with the pharmacist's intervention, with a scale from 0 to 10 | 3 months after intervention | — |
| Changes in lifestyle related to asthma (free text field to complete by the patient) | 3 months after intervention | — |
| Change from Baseline MRA (Medication Refill Adherence) at 3 months | 3 months | Measure of treatment adherence |
Outcome results
None listed